Neurimmune Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 68

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

Neurimmune General Information

Description

Operator of a biopharmaceutical company intended to translate human immune memory into antibody therapeutics. The company translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • Wagistrasse 18
  • 10th floor
  • 8952 Zurich
  • Switzerland
+41 044
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • Wagistrasse 18
  • 10th floor
  • 8952 Zurich
  • Switzerland
+41 044

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 01-Jan-2011 Completed Generating Revenue
1. Spin-Off 14-Nov-2006 Completed Generating Revenue
To view Neurimmune’s complete valuation and funding history, request access »

Neurimmune Patents

Neurimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016205988-A1 Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof Inactive 09-Jan-2015
CA-2973040-A1 Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof Inactive 09-Jan-2015
EP-3242683-A1 Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof Inactive 09-Jan-2015
US-20170369592-A1 Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof Inactive 09-Jan-2015
WO-2016110598-A1 Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof Inactive 09-Jan-2015 C07K16/40
To view Neurimmune’s complete patent history, request access »

Neurimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurimmune Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
University of Zürich University Minority
To view Neurimmune’s complete investors history, request access »

Neurimmune Investments (4)

Neurimmune’s most recent deal was a Later Stage VC with NovaGo Therapeutics for . The deal was made on 31-Aug-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NovaGo Therapeutics 31-Aug-2026 Later Stage VC Drug Discovery
NovaGo Therapeutics 04-Mar-2019 Early Stage VC Drug Discovery
AL-S Pharma 30-Jan-2018 Early Stage VC Drug Discovery
AL-S Pharma 07-Dec-2016 Early Stage VC Drug Discovery
To view Neurimmune’s complete investments history, request access »

Neurimmune FAQs

  • When was Neurimmune founded?

    Neurimmune was founded in 2006.

  • Where is Neurimmune headquartered?

    Neurimmune is headquartered in Zurich, Switzerland.

  • What is the size of Neurimmune?

    Neurimmune has 68 total employees.

  • What industry is Neurimmune in?

    Neurimmune’s primary industry is Drug Discovery.

  • Is Neurimmune a private or public company?

    Neurimmune is a Private company.

  • What is Neurimmune’s current revenue?

    The current revenue for Neurimmune is .

  • Who are Neurimmune’s investors?

    University of Zürich has invested in Neurimmune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process